CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients. Author Response. (Record no. 26971167)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 00866 a2200217 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250517143338.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | ####s 0 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 1526-632X |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1212/01.wnl.0000496643.57775.41 |
| Source of number or code | doi |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | NLM |
| Language of cataloging | eng |
| Transcribing agency | NLM |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Cahir-McFarland, Ellen |
| 245 00 - TITLE STATEMENT | |
| Title | CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients. Author Response. |
| Medium | [electronic resource] |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Name of publisher, distributor, etc. | Neurology |
| Date of publication, distribution, etc. | 08 2016 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 958-9 p. |
| Other physical details | digital |
| 500 ## - GENERAL NOTE | |
| General note | Publication Type: Journal Article; Comment |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Ransohoff, Richard M |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Lieberman, Linda |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Plavina, Tatiana |
| 773 0# - HOST ITEM ENTRY | |
| Title | Neurology |
| Related parts | vol. 87 |
| -- | no. 9 |
| -- | p. 958-9 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://doi.org/10.1212/01.wnl.0000496643.57775.41">https://doi.org/10.1212/01.wnl.0000496643.57775.41</a> |
| Public note | Available from publisher's website |
No items available.